Regeneron Pharmaceuticals (REGN) said Monday it has won the bankruptcy auction to acquire substantially all assets of 23andMe for $256 million.
The acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services business units, its Biobank, and related assets. The transaction does not include 23andMe's Lemonaid Health business.
The deal is expected to close in Q3, pending closing conditions including bankruptcy court and regulatory approvals.
Following the acquisition, 23andMe will operate as a wholly owned subsidiary of Regeneron and continue its personal genomics services.
Regeneron said it will maintain compliance with 23andMe's consumer privacy policies and applicable laws with respect to the treatment of customer data.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。